Meet the "Magnificent Seven" Stock That Pays More Dividends Than Any Other U.S.-Based Company
https://www.fool.com/investing/2024/03/16/magnificent-seven-stock-pays-most-dividends/?source=iedfolrf0000001
Mar 16, 2024 - Microsoft is the complete package.
0
Johnson & Johnson (JNJ), Nvidia Unite to Boost AI for Surgery
https://www.zacks.com/stock/news/2242895/johnson-johnson-jnj-nvidia-unite-to-boost-ai-for-surgery?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2242895
Mar 19, 2024 - Johnson & Johnson (JNJ) collaborates with Nvidia to facilitate the creation of AI-based models and the deployment of applications, offering a route to scale within its digital ecosystem for surgery.
0
Pharma Stock Roundup: AZN to Buy FUSN, PFE to Sell Stake in HLN & Other Updates
https://www.zacks.com/stock/news/2245062/pharma-stock-roundup-azn-to-buy-fusn-pfe-to-sell-stake-in-hln-other-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-2245062
Mar 22, 2024 - AstraZeneca (AZN) is set to acquire Fusion Therapeutics (FUSN). Pfizer (PFE) plans to sell some shares of Haleon to lower stake from 32% to 24%.
0
Pharma Stock Roundup: ABBV & NVO's New M&As, FDA Nod to JNJ & MRK PAH Drugs
https://www.zacks.com/stock/news/2247400/pharma-stock-roundup-abbv-nvo-s-new-m-as-fda-nod-to-jnj-mrk-pah-drugs?cid=CS-ZC-FT-analyst_blog|stock_roundup-2247400
Mar 28, 2024 - While AbbVie (ABBV) is set to buy Landos Biopharma, Novo Nordisk (NVO) is set to acquire Cardior Pharmaceuticals. FDA approves J&J's (JNJ) and Merck's (MRK) PAH drugs.
0
Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report?
https://www.zacks.com/stock/news/2249996/will-johnson-johnson-jnj-beat-estimates-again-in-its-next-earnings-report?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_7-2249996
Apr 03, 2024 - Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
0
Bristol Myers (BMY) Gets FDA Nod for Label Expansion of Abecma
https://www.zacks.com/stock/news/2252179/bristol-myers-bmy-gets-fda-nod-for-label-expansion-of-abecma?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2252179
Apr 08, 2024 - Bristol Myers (BMY) wins FDA approval for CAR T cell immunotherapy, Abecma, in earlier lines of treatment for patients with relapsed or refractory multiple myeloma.
0
Housing Numbers Shrink as Q1 Earnings Heat Up: BAC, JNJ, UNH
https://www.zacks.com/stock/news/2256163/housing-numbers-shrink-as-q1-earnings-heat-up-bac-jnj-unh?cid=CS-ZC-FT-ahead_of_wall_street-2256163
Apr 16, 2024 - Both Housing Starts and Building Permits missed expectations, while BofA, J&J and UnitedHealth all beat on earnings.
0
J&J (JNJ) Q1 Earnings Beat Estimates, Sales Miss, MedTech Soft
https://www.zacks.com/stock/news/2256185/j-j-jnj-q1-earnings-beat-estimates-sales-miss-medtech-soft?cid=CS-ZC-FT-analyst_blog|earnings_article-2256185
Apr 16, 2024 - J&J (JNJ) beats estimates for first-quarter earnings but misses the same for sales. It tightens its sales and earnings growth expectations for 2024.
0